PharmTech Drug Digest 11.20
News|Articles|October 27, 2026

Beyond Triton X-100: Evaluating Viral Inactivation Strategies for Modern Bioprocessing

Author(s)Avantor

As Triton X-100 faces growing regulatory and sustainability challenges, biopharmaceutical manufacturers are evaluating alternatives for detergent-based viral inactivation. This whitepaper examines key considerations for replacing Triton X-100, including viral clearance, product quality, process compatibility, residual clearance, and implementation, while sharing data on J.T.Baker® Viral Inactivation Solution.


Related to this article